What Is GLP-1 and Where Does It Come From?

Glucagon-like peptide-1 is a 30-amino-acid incretin hormone produced mainly by L-cells lining the small intestine and colon. The body releases it within minutes of eating, particularly after meals containing carbohydrates and fats. Its name comes from the fact that its gene sequence overlaps with glucagon, though the two hormones have opposite effects on blood sugar.

Once released, endogenous GLP-1 has a very short working life. The enzyme dipeptidyl peptidase-4 (DPP-4) cleaves it within one to two minutes, so circulating levels drop quickly after the initial post-meal spike. This rapid degradation is why researchers spent decades trying to engineer longer-lasting versions that could be used therapeutically.

GLP-1 acts on receptors found in the pancreas, brain, stomach, heart, and kidneys. The pancreatic signal is the most studied: GLP-1 binds to the GLP-1 receptor on beta cells, which boosts insulin secretion only when blood glucose is already elevated. That glucose-dependence is a key feature because it means the signal naturally quiets down when blood sugar returns to normal range.

How Does a GLP-1 Receptor Agonist Work at the Molecular Level?

The GLP-1 receptor is a class B G-protein-coupled receptor (GPCR). When an agonist binds to it, the receptor activates a Gs protein, which in turn raises intracellular cyclic AMP (cAMP). Elevated cAMP activates protein kinase A and exchange proteins directly activated by cAMP (Epac2), both of which promote the release of insulin-containing vesicles from pancreatic beta cells.

Synthetic GLP-1 receptor agonists are designed to bind the same receptor as endogenous GLP-1 but resist DPP-4 cleavage, which dramatically extends their half-life. Depending on the compound, half-life ranges from hours to more than a week. Semaglutide, for example, has a half-life of roughly seven days, which is why it can be administered once weekly in its approved pharmaceutical forms.

Beyond the pancreas, receptor activation in the hypothalamus and brainstem reduces appetite and increases satiety signals. Activation in the stomach slows gastric emptying, which blunts post-meal glucose spikes and prolongs the feeling of fullness. These central and peripheral effects together explain why this drug class has attracted interest well beyond glycemic control alone.

Researchers have also identified GLP-1 receptors in cardiac tissue and the kidneys. Several large cardiovascular outcome trials have shown that approved GLP-1 receptor agonist drugs reduce major adverse cardiovascular events in people with type 2 diabetes and established cardiovascular disease, though the exact mechanisms behind those cardiovascular findings are still being studied.

Endogenous GLP-1 vs. Synthetic Agonists: What's Different?

The body's own GLP-1 and a synthetic agonist both activate the same receptor, but they are not the same molecule. Endogenous GLP-1 is degraded in under two minutes. Synthetic agonists are structurally modified to survive DPP-4 and, in some cases, are attached to albumin-binding fatty acid chains (as with semaglutide and liraglutide) to further extend their circulation time.

This prolonged exposure changes the pharmacodynamic picture. A once-weekly injection maintains receptor activation continuously rather than in the brief post-meal pulses the body produces naturally. Whether continuous activation replicates, amplifies, or subtly alters the physiological signal is an active area of research. Some studies suggest continuous receptor engagement may contribute to the gastric-emptying slowdown more than the acute post-meal pulse does.

There is also a structural diversity in the class. Exenatide, one of the earliest approved agonists, was derived from a peptide found in Gila monster saliva called exendin-4. It shares about 53% sequence homology with human GLP-1. Semaglutide and liraglutide are closer analogs of human GLP-1, with single amino acid substitutions and fatty acid attachments. These structural differences affect binding kinetics, receptor internalization rates, and side-effect profiles.

The Drug Class Landscape

Several GLP-1 receptor agonists have received FDA approval as prescription drugs. Liraglutide was approved under the brand names Victoza (for type 2 diabetes, 2010) and Saxenda (for chronic weight management, 2014). Semaglutide is approved as Ozempic (injectable, type 2 diabetes), Rybelsus (oral tablet, type 2 diabetes), and Wegovy (higher-dose injectable, chronic weight management). Exenatide was approved as Byetta and later as the extended-release Bydureon. Dulaglutide (Trulicity) and tirzepatide (Mounjaro, Zepbound) round out the current approved options, though tirzepatide is technically a dual GIP/GLP-1 receptor agonist rather than a pure GLP-1 agonist.

All of these are prescription-only medications in the United States. They are not available over the counter, and research-chemical versions sold online are not FDA-approved. The FDA approval belongs to the specific branded pharmaceutical product, not to the peptide sequence in general. Readers who see semaglutide or liraglutide sold as research chemicals are looking at compounds that carry none of the regulatory oversight applied to the approved drugs.

The pipeline continues to expand. Oral semaglutide (Rybelsus) demonstrated in a 2019 New England Journal of Medicine trial (the PIONEER 1 trial, n=703) that a GLP-1 agonist could achieve meaningful glycemic reduction via the oral route, which had long been considered impractical for peptide drugs due to gastrointestinal degradation. Researchers are also studying longer-acting formulations, combination agonists targeting additional receptors, and non-peptide small-molecule GLP-1 receptor agonists.

What the Evidence Record Looks Like

GLP-1 receptor agonists are among the most extensively studied drug classes in recent metabolic medicine. The LEADER trial (2016, New England Journal of Medicine, n=9,340) showed that liraglutide reduced the rate of major adverse cardiovascular events compared to placebo in adults with type 2 diabetes and high cardiovascular risk. The SUSTAIN-6 trial (2016, n=3,297) showed similar findings for semaglutide. These are large, randomized, placebo-controlled trials, which places them at the top of the clinical evidence hierarchy.

Weight-loss data for higher-dose formulations also comes from large RCTs. The STEP 1 trial (2021, New England Journal of Medicine, n=1,961) found that participants receiving once-weekly 2.4 mg semaglutide lost an average of 14.9% of body weight over 68 weeks compared to 2.4% in the placebo group. These are human RCT findings, the strongest evidence tier available.

Most of the mechanistic work, meaning the receptor-binding studies, the cAMP pathway mapping, and the brain-signaling research, comes from animal models and in-vitro cell studies. Those findings are what built the theoretical framework, but the clinical outcomes data in humans is what established the class as a major therapeutic category. The two evidence tiers serve different purposes and should not be conflated.

Frequently asked questions

Is there a difference between a GLP-1 receptor agonist and a GLP-1 supplement?

Yes, and the difference is significant. Approved GLP-1 receptor agonists are prescription drugs that directly bind and activate the GLP-1 receptor with a documented pharmacological effect. GLP-1 supplements, typically sold over the counter, contain ingredients like berberine or certain fiber compounds that may modestly stimulate the body's own GLP-1 secretion. The mechanisms are entirely different, and the evidence supporting supplement-based approaches is far weaker than the large RCT data behind approved agonist drugs. No supplement has been shown to replicate the receptor-level activity of a pharmaceutical GLP-1 agonist.

Why do GLP-1 receptor agonists cause nausea in some people?

Nausea is the most commonly reported side effect across the class, and it's directly tied to the mechanism. GLP-1 receptors are present in the area postrema, a brain region involved in triggering nausea and vomiting, and in the gastrointestinal tract. Slowing gastric emptying also contributes to the sensation. In clinical trials, nausea was typically most pronounced during the early weeks of treatment and tended to diminish over time. The STEP 1 trial reported nausea in approximately 44% of participants in the semaglutide group versus 16% in the placebo group, though most cases were mild to moderate.

Do GLP-1 receptor agonists work the same way in people without diabetes?

The receptor-level mechanism is the same regardless of diabetes status. The glucose-dependent insulin secretion pathway activates in anyone with a functional GLP-1 receptor, but because the signal requires elevated blood glucose to trigger meaningful insulin release, the glycemic effect is naturally limited in people with normal glucose regulation. The appetite-suppressing and gastric-emptying effects, however, operate independently of diabetes status, which is why regulatory agencies have approved certain formulations specifically for weight management in people without diabetes, provided they meet other clinical criteria. A physician determines whether any of these medications is appropriate for a given individual.

Sources

  1. Drucker DJ, 2006, Cell Metabolism, GLP-1 biology and therapeutic applications Foundational review of GLP-1 receptor signaling
  2. Marso et al., 2016, New England Journal of Medicine, LEADER trial, liraglutide cardiovascular outcomes Large RCT supporting cardiovascular benefit claims
  3. Wilding et al., 2021, New England Journal of Medicine, STEP 1 trial, semaglutide weight loss RCT data on weight outcomes cited in article
  4. Aroda et al., 2019, New England Journal of Medicine, PIONEER 1 trial, oral semaglutide Supports oral GLP-1 agonist feasibility discussion

Educational and informational content only. This is not medical advice, diagnosis, or treatment. The compounds discussed are research compounds that are not approved for human use outside specific prescribed contexts. Always consult a qualified, licensed clinician before making any health decision.